ClinicalTrials.gg
RecruitingNCT05614024Updated Nov 4, 2026

Neurofeedback During Eating for Bulimia Nervosa

An interventional study of Real fNIRS Neurofeedback and Sham-Control fNIRS Neurofeedback in Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Bulimia Nervosa with a site in United States — 14 open to participants now, 20 under way, none of them phase 3. Bulimia Nervosa · United States.

Planned enrollment
40th of 68
30 · median 42
Started
2024
with 5 others
No phase
56 of 87
9 open now
Primary completion
2027-12
later than 11 of 19 live
Registered
69th of 87
by date
Lead sponsor
6 of 87
Icahn School of Medicine at Mount Sinai

Among the 87 studies in Bulimia Nervosa with a site in United States, this one is the 40th largest by planned enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2024, is one of 56 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 69th registered.

Bulimia Nervosa

173 studies on the registry are indexed under Bulimia Nervosa; 38 are open to participants now.

Browse Bulimia Nervosa studies →

Open to participants now

14 of the 87 studies in Bulimia Nervosa with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Bulimia Nervosa studies recruiting now, 9 (29%) set no upper age limit and 20 (65%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Bulimia Nervosa with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.

Read the detailed description

The purpose of this study is to examine the effects of PFC neurofeedback during eating in women with bulimia nervosa (BN) using fNIRS. Specifically, the study aims 1) to demonstrate ventrolateral PFC (vlPFC) neurofeedback target engagement in women with BN using fNIRS; and 2) to link changes in PFC activation to changes in inhibitory control and eating-related symptoms.

Data will be collected from women with BN who will be randomly assigned to one of two group conditions (real or sham-control neurofeedback during eating). Participation includes a phone screening assessment, psychodiagnostic assessment, one in-person evaluation, one neurofeedback session, behavioral tasks, online questionnaires before and after the neurofeedback session, and a remote follow-up assessment.

03

Conditions studied

  • Bulimia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Aged 18 to 45 years
  • Meet diagnostic criteria for bulimia nervosa
  • Current greater than or equal to 18.5kg/m2 but under 30kg/m2
  • English-speaking

Exclusion criteria

Exclusion criteria:

  • Ongoing medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation
  • Current psychotherapy focused primarily on eating disorder symptoms
  • Pregnancy or planned pregnancy, or lactation during the study period
  • Allergy to ingredients in the standardized meal or in the shake
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Real fNIRS Neurofeedback Arm

    Participants assigned to the experimental arm will see their true, real-time brain activation (i.e., active real-time neurofeedback) during the neurofeedback session. This activation will be displayed to the participant as a thermometer that will increase as brain activation in the target region increases.

    Other: Real fNIRS Neurofeedback

  • Sham comparator
    Sham-Control fNIRS Neurofeedback Arm

    Participants assigned to the sham-control arm will see false feedback (or a fake signal) that is not connected to their right vlPFC activation during the neurofeedback session.

    Other: Sham-Control fNIRS Neurofeedback

Interventions

  • OtherReal fNIRS Neurofeedback

    Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.

  • OtherSham-Control fNIRS Neurofeedback

    Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.

06

What researchers measure

Primary outcomes

  1. Functional near-infrared spectroscopy (fNIRS)-measured neural activation and connectivity

    The investigators will evaluate changes in PFC neural activation and connectivity as a function of neurofeedback.

    Time frame: approximately 1 hour

  2. Go/no-go task performance

    Participants will complete a go/no-go task 1 week before and 1 week after the neurofeedback session to measure inhibitory control. Participants behavioral performance on the go/no-go task will be determined by the percentage of incorrect responses made as they are prompted to react to different pictorial stimuli. Participants' percentages of error can range from 0% to 100%. A higher percentage indicates a lower behavioral performance on the task.

    Time frame: 2 weeks

  3. Number of loss-of-control eating and purging episodes

    Frequency of loss-of-control eating and purging episodes. Participants will self-report on how often loss-of-control eating and purging episodes occur using electronic daily diaries in the week before and the week after the neurofeedback session.

    Time frame: 2 weeks

  4. Severity of loss-of-control eating scale

    Severity of loss-of-control eating. Participants will rate the severity of their feelings of control over eating and purging episodes on a Likert-type scale from 0-10. Higher score indicates greater severity of loss of control.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
  • Center for Computational Psychiatry at the Icahn School of Medicine at Mount Sinai
    New York, New York 10027, United States
    Recruiting
    • Laura A. Berner · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Statistical analysis plan

Time frame: Immediately following publication and ending 5 years following article publication.

Access criteria: Researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. Proposals should be directed to laura.berner@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years after article publication via direct request to the investigator.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 43 months after the start.

Of 62 non-industry interventional studies with no phase under Bulimia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 43 months is close to that.

Counting every sponsor, half of 64 studies reached it within 43 months; a quarter within 18 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 14, 2022
StartActual
May 13, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05614024
Responsible party
Laura Berner (Assistant Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Nov 14, 2022
Start date
May 13, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Sila Sozeri, B.A.
Contact
sila.sozeri@mssm.edu
(212) 201-2679
Laura A Berner, Ph.D.
Contact
laura.berner@mssm.edu
Laura A Berner, Ph.D.
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion